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Background:  Short term effect of sildenafil on pulmonary arterial pressure and platelet activity thalassemia patients with pulmonary arterial 
hypertension Navy Tanjararak, MD, Suporn Chuncharunee, MD, Nathawut Sibmooh, PhD, Sukit Yamwong, MD, Somruthai Wattanachai, B.S., Piyamitr 
Sritara, MD Cardiology unit, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University. Thalassemia is the most 
common important problem disease in Thailand. Pulmonary arterial hypertension (PAH) are common complications in thalassemia intermedia 
especially thalassemia major patient. Enhanced platelet activation is one of many factors to have a role in PAH. Adequate blood transfusion and iron 
chelator are standard of care in these patients. Evidence-based vasodilator treatments of PAH in thalassemia are lack.
methods: We enrolled 34 thalassemia patients, most of them are beta-heterozygous E thalassemia with splenectomized. We measured pulmonary 
arterial pressure (represent by right ventricular systolic pressure, RVSP) by echocardiography and platelet activity at baseline and categorized 
patients in two groups, RVSP was more than 36 mmHg defined PAH group. Thirteen of thalassemia patients with PAH group were recieved sildenafil 
75 mg per day for 42 days and re-evaluated pulmonary pressure and platelet activity at 14 and 42 days.
Results: Baseline of thalassemia with PAH group were female 69%, mean age was 35 years, mean RVSP was 57.83 +/- 3.55 mmHg, mean 
P-selectin activity was 18.78% +/- 5.51, mean GPIIb/IIIa activity was 11.54%+/- 6.19. At 14 days follow-up, mean RVSP was 53.58 +/- 4.58 (p 
value = 0.16), mean P-selectin was 14.56% +/- 4.21 (P-value 0.008), mean GPIIb/IIIa was 6.73% +/- 4.43 (p-value = 0.024).
conclusion: Sildenafil have effect on reduction of platelet activity add on conventional treatment in thalassemia patients and trend to reduce 
pulmonary pressure in these patients.
